Brickell Cash per Share

BBI
 Stock
  

USD 3.27  0.39  10.66%   

Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
The current Free Cash Flow is estimated to decrease to about (37.1 M).

Brickell Cash per Share Analysis

Brickell Biotech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
 2019 2020 2021 2022 (projected)
Revenues USD7.92 M1.82 M404 K414.63 K
Revenues7.92 M1.82 M404 K414.63 K
Cash per Share 
 = 
Total Cash 
Average Shares 
More About Cash per Share | All Equity Analysis

Current Brickell Biotech Cash per Share

    
  6.52 X  
Most of Brickell Biotech's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Brickell Cash per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Brickell Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Cash per Share. Since Brickell Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brickell Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brickell Biotech's interrelated accounts and indicators.

Brickell Cash per Share Historical Pattern

Today, most investors in Brickell Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Brickell Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Brickell Biotech cash per share as a starting point in their analysis.
   Brickell Biotech Cash per Share   
Share
       Timeline  
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Compare to competition
In accordance with the recently published financial statements, Brickell Biotech has a Cash per Share of 6.52 times. This is 49.89% higher than that of the sector and 50.58% higher than that of the Cash per Share industry. The cash per share for all United States stocks is 30.14% lower than that of the firm.

Brickell Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brickell Biotech's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brickell Biotech could also be used in its relative valuation, which is a method of valuing Brickell Biotech by comparing valuation metrics of similar companies.
Brickell Biotech is currently under evaluation in cash per share category among related companies.

Brickell Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brickell Biotech from analyzing Brickell Biotech's financial statements. These drivers represent accounts that assess Brickell Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brickell Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(122.58 K)(175.13 K)(541.8 K)(1.59 M)(1.83 M)(1.88 M)
Revenue Per Employee198.51 K186.74 K54.07 K527.8 K475.02 K512.52 K
Average Assets58.08 M45.63 M34.66 M25.13 M30.46 M39.21 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(12.17 M)(8.1 M)(21.75 M)(20.9 M)(39.38 M)(40.42 M)
Earnings before Tax(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Average Equity45.92 M23.07 M27.82 M17.91 M24.09 M32.33 M
Enterprise Value12.67 M13.45 M4.59 M22.04 M4.97 M5.1 M
Free Cash Flow(8.68 M)3.96 M(35.99 M)(20.06 M)(36.18 M)(37.14 M)
Invested Capital37.84 M(15.21 M)488 K(2.4 M)(1.98 M)(2.03 M)
Invested Capital Average32.37 M28.85 M20.09 M(1.32 M)(2.55 M)(2.62 M)
Market Capitalization23.07 M25.74 M11.72 M41.77 M26.33 M27.03 M
Tangible Asset Value79.79 M8.31 M18.14 M33.63 M29.72 M36.69 M
Working Capital59.4 M(11.82 M)7.47 M27.18 M24.79 M28.97 M

Brickell Fundamentals

About Brickell Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Free Cash Flow-36.2 M-37.1 M
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brickell Biotech

0.68ACSTAcasti Pharma Earnings Call  TodayPairCorr
0.82ADTXAditxt Inc Earnings Call  TomorrowPairCorr

Moving against Brickell Biotech

0.91AGLAgilon Health Downward RallyPairCorr
0.88ALTAltimmune Earnings Call  TodayPairCorr
0.84ARTLArtelo Biosciences SplitPairCorr
0.82ADGIAdagio Therapeutics Earnings Call  TomorrowPairCorr
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brickell Biotech Piotroski F Score and Brickell Biotech Altman Z Score analysis. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
9.9 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.